Article Sidebar

PDF
Date Published: 13/03/2022
Abstract Views: 556
Views PDF: 235
DOI: https://doi.org/10.51298/vmj.v510i2.1998
Issue
Vol. 510 No. 2 (2022)
Section
Các bài báo
How to Cite
Vĩnh Niên, L. ., Thanh Trầm, N. ., Lê Hà Anh, N. ., & Trí Thanh, V. . (2022). SERUM HIGH-SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) IN ASSEMENT OF CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETIC PATIENTS. Vietnam Medical Journal, 510(2). https://doi.org/10.51298/vmj.v510i2.1998

SERUM HIGH-SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) IN ASSEMENT OF CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETIC PATIENTS

Lâm Vĩnh Niên1,, Nguyễn Thanh Trầm1, Nguyễn Lê Hà Anh1, Vũ Trí Thanh2
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 University Medical Center Ho Chi Minh City branch 2

Main Article Content

Abstract

Background: Assessment of serum hs-CRP according to cardiovascular risk with characteristics in diabetic patients is necessary to support treatment timely for these patients. Material and methods: Cross-sectional study. Analysis of hs-CRP levels of 118 type 2 diabetic patients, who came for examination and treatment at the University Medical Center Ho Chi Minh City 2nd from September 2020 to June 2021. Results: Most of the patients were female. There were 33.1% of patients who were overweight or obseve, and 64.4% of patients had hypertension. The mean hs-CRP concentration was 3.9±1.7mg/L, and belonged to high-risk cardiovascular. The mean fasting blood glucose concentration of 174.1±82.8 mg/dL and the mean HbA1c index of 8.3±2.4 mg/dL were also distributed mainly within the high cardiovascular risk threshold. At a high-risk cardiovascular threshold, those with a BMI of less than 25 kg/m2 were significantly different from the other groups (p = 0.015). Conclusion: High hs-CRP levels and cardiovascular risk were associated with BMI, high blood glucose and the HbA1c index, but no association was found with other characteristics such as age, sex, period of time and hypertension.

Article Details

Keywords

hs-CRP, cardiovascular disease risk, type 2 diabetic

References

1. Wild S, Roglic G, Green A, Sicree R, King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care; 27(5):1047–53.
2. Stratton IM, Adler AI, Neil HA, et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ; 321(7258):405–12.
3. Mazidi M, Toth PP, Banach M. (2018). C-reactive protein is associated with prevalence of the metabolic syndrome, hypertension, and diabetes mellitus in US adults. Angiology; 69(5):438–42.
4. Hwang YC, Morrow DA, Cannon CP, et al. (2018). High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (examination of cardiovascular outcomes with Alogliptin versus standard of Care) trial. Diabetes Obes Metab; 20(3):654–9.
5. Al-Shukaili A, et al. (2013). Analysis of inflammatory mediators in type 2 diabetes patients. International journal of endocrinology, pp. 7.
6. Kanter JE, et al. (2008). "Diabetes-accelerated atherosclerosis and inflammation". Circulation research, 103 (8), p116-117.
7. American Diabetes Association (2020) "Standards of medical care in diabetes ". Diabetes Care 43 (1), p 7-14.
8. Garcia, VP, Rocha HN, Sales AR, Rocha NG, & da Nóbrega AC (2016). Sex Differences in High Sensitivity C-Reactive Protein in Subjects with Risk Factors of Metabolic Syndrome. Arquivos brasileiros de cardiologia, 106(3), 182–187.